The cardiovascular safety construct on this page refers only to mechanistic PK/PD determinants that connect drug exposure with vascular signaling and systemic hemodynamic transitions. Within a comparison overview of sildenafil and vardenafil, the analysis focuses on how exposure geometry is formed and translated into cardiovascular pathway engagement, without interpreting those processes as clinical outcomes. Absorption establishes systemic input, distribution determines movement between plasma and relevant compartments, metabolism modifies parent-compound exposure, and elimination shapes subsequent concentration decline. Half life provides one descriptor of concentration persistence, while broader PK differences describe the geometry of the complete exposure trajectory. These processes determine when concentrations rise, approach peak regions, redistribute, and decline. Cardiovascular interpretation therefore begins with exposure formation rather than with an isolated hemodynamic endpoint. The central mechanistic question is how concentration trajectories establish the temporal conditions under which vascular PDE5 interaction and downstream signaling can occur.
The pharmacodynamic component is represented by PD differences, particularly concentration-dependent PDE5 interaction and downstream NO–cGMP signaling in vascular smooth muscle. As drug concentration changes, the degree of modeled PDE5 interaction can change, altering the balance of cGMP degradation and persistence within the relevant signaling pathway. This creates a concentration–effect relationship in which vascular pathway engagement develops along the exposure trajectory rather than at one fixed time. Vasodilation can therefore be treated as a mechanistic PK→PD transition: systemic concentration changes, target-compartment concentration changes, PDE5 interaction changes, NO–cGMP signaling changes, and smooth-muscle relaxation follows within the modeled pathway. Effectiveness is used only as a mechanistic PD construct describing pathway engagement relative to concentration and target interaction, not as a clinical effectiveness claim. Onset speed describes the timing of early concentration-dependent transitions, while duration length describes persistence of exposure and pathway engagement during subsequent decline.
Cardiovascular timing also depends on variability in the coupled PK/PD trajectory. Variability can occur in absorption, distribution, metabolism, elimination, target-compartment exposure, and concentration–effect mapping. Interindividual variability describes differences among modeled exposure and pathway trajectories, while clinical variability is treated only as a descriptive category rather than evidence of a clinical outcome. Sildenafil and vardenafil can therefore be represented through distinct concentration geometries that enter a related PDE5–NO–cGMP signaling framework. An ascending exposure phase can correspond to increasing pathway engagement, while a declining phase can correspond to progressive reduction in target interaction and signaling within the model. Distribution gradients may separate plasma concentration from vascular-compartment concentration, and metabolic or elimination processes may alter persistence. The resulting cardiovascular PK/PD construct describes how exposure-driven concentration transitions couple to vasodilation and systemic hemodynamic behavior without assigning those transitions a clinical meaning or ranking one compound against the other.
Cardiovascular PK/PD foundations describe how systemic drug exposure is translated into vascular pathway engagement and modeled hemodynamic transitions. The cardiovascular safety construct is therefore treated as a mechanistic relationship rather than a clinical endpoint. PK differences determine how concentration trajectories are formed, while PD differences describe how those concentrations interact with PDE5 and downstream signaling. Absorption establishes the systemic input function and contributes to the initial concentration rise. Distribution then determines how concentration moves between plasma and vascular or other modeled compartments. The resulting exposure geometry provides the temporal input for concentration–effect behavior. As concentration rises, target availability can increase; as concentration declines, target interaction can diminish. Vasodilation is consequently represented as a downstream pathway transition coupled to concentration rather than as an independent event. This framework permits sildenafil and vardenafil to be compared through the architecture of exposure formation and vascular pathway coupling without converting mechanistic differences into clinical conclusions.
Vasodilation can be modeled as a sequence connecting target interaction with smooth-muscle signaling. After systemic exposure reaches the relevant compartment, drug concentration becomes available for PDE5 interaction. PDE5 inhibition alters cGMP degradation within the NO–cGMP pathway, changing the signaling environment that regulates vascular smooth-muscle tone. The concentration–effect relationship therefore links the PK trajectory to a progressive PD trajectory. The timing of this transition depends on exposure geometry, including the rate of concentration rise, distribution between compartments, and subsequent decline. An early ascending concentration phase can generate an early increase in modeled pathway engagement, while later exposure persistence can maintain the signaling environment before concentration decreases. The cardiovascular safety framework thus distinguishes concentration formation from pathway response. PK differences describe the former, while PD differences describe the latter. The mechanistic coupling is expressed through concentration-dependent PDE5 interaction, NO–cGMP signaling, smooth-muscle relaxation, and the resulting modeled vascular transition.
Systemic hemodynamic transitions can be conceptualized as downstream consequences of changing vascular tone within the mechanistic model. They are not treated here as clinical outcomes. The relevant sequence begins with systemic exposure, proceeds through distribution to the target compartment, and then connects concentration-dependent PDE5 interaction with NO–cGMP signaling and smooth-muscle relaxation. A change in exposure geometry can therefore shift the timing of the modeled vascular transition without requiring a change in the underlying molecular target. Differences between sildenafil and vardenafil can be represented through differences in absorption, distribution, metabolic turnover, and elimination, which alter when and for how long target-relevant concentrations are present. Absorption influences the early input phase, while distribution influences compartmental concentration. The resulting trajectory enters the concentration–effect relationship described by PD differences. This makes cardiovascular PK/PD analysis a coupled temporal model in which exposure geometry controls the timing of pathway availability and pathway engagement provides the downstream interpretation.
Cardiovascular PK determinants are the disposition processes that establish the concentration trajectory available for vascular pathway interaction. Absorption determines the rate and extent of systemic drug entry, shaping the ascending exposure phase. Distribution controls movement between plasma and other compartments, including the potential formation of concentration gradients between systemic and vascular target regions. Metabolism transforms parent compound and contributes to subsequent exposure decline, while elimination integrates processes that remove drug from the systemic compartment. For sildenafil and vardenafil, these determinants can produce distinct exposure geometries even within a shared PDE5-targeting framework. A difference in absorption rate can shift the timing of early concentration transitions, while a distribution difference can alter the relationship between plasma exposure and target-compartment concentration. Metabolic turnover and elimination then influence the descending trajectory. The cardiovascular relevance of these PK processes is therefore temporal and mechanistic: they determine when vascular target concentrations emerge, how they change, and how long they remain within particular concentration–effect regions.
Exposure geometry contains multiple interconnected phases rather than a single cardiovascular parameter. The early rise reflects systemic input, the peak region reflects the balance between input and disposition, and the decline reflects distribution, metabolism, and elimination. Absorption can therefore influence the initial slope, while distribution can produce additional phases or gradients. Metabolism contributes to transformation of the parent compound, and elimination determines the overall removal trajectory. These processes shape the concentration available for PDE5 interaction in vascular compartments. The resulting concentration–effect transition can influence the modeled timing of smooth-muscle relaxation and vasodilation. Importantly, the PK process itself is not the vascular response; it provides the exposure trajectory that drives the downstream PD model. Sildenafil and vardenafil can therefore be described through their respective exposure geometries without assigning a clinical interpretation. Cardiovascular PK analysis remains focused on concentration formation, compartmental movement, persistence, and decline.
The coupling between PK geometry and vascular pathway engagement is strongest when concentration changes are considered relative to target-compartment kinetics. Plasma concentration can rise before distribution has fully equilibrated with a vascular compartment, creating a temporal gradient between systemic exposure and local concentration. Conversely, plasma decline can occur while another compartment retains a different concentration profile. This makes distribution an important bridge between systemic PK and cardiovascular PD. Absorption establishes the initial input, metabolism modifies the parent-compound trajectory, and elimination determines progressive removal. The resulting exposure geometry determines when the concentration enters or leaves a modeled PDE5 concentration–effect region. Thus, cardiovascular pathway timing can be represented as a coupled sequence rather than a direct consequence of any single PK parameter. Differences between sildenafil and vardenafil are interpreted through this sequence, preserving the distinction between disposition processes, vascular target interaction, NO–cGMP signaling, and smooth-muscle relaxation.
| Cardiovascular Determinant | PK Basis | Role in Exposure Geometry |
|---|---|---|
| Absorption rate | Rate of systemic drug entry | Shapes the ascending concentration phase and the timing of early target exposure. |
| Absorption extent | Fraction of administered compound reaching systemic circulation | Influences the magnitude of exposure available for vascular target interaction. |
| Distribution | Movement between plasma and tissue or modeled vascular compartments | Creates concentration gradients and can separate plasma timing from target-compartment timing. |
| Metabolic turnover | Biotransformation of parent compound | Contributes to concentration decline and modifies persistence of parent-compound exposure. |
| Elimination | Removal through metabolic and excretory pathways | Shapes the descending concentration trajectory and later exposure persistence. |
| Coupled disposition | Combined effects of absorption, distribution, metabolism, and elimination | Determines the composite timing and curvature of cardiovascular-relevant exposure geometry. |
Cardiovascular PD determinants describe how concentration at the relevant biological compartment is translated into vascular pathway engagement. PD differences can be represented through concentration-dependent PDE5 interaction and the resulting modulation of NO–cGMP signaling. When a PDE5 inhibitor reaches the target compartment, its concentration influences the degree of PDE5 interaction within the mechanistic model. Reduced PDE5-mediated cGMP degradation allows cGMP signaling to persist differently under the relevant pathway conditions, providing a molecular link to vascular smooth-muscle relaxation. The pathway is therefore concentration dependent and temporally coupled to PK exposure. Distribution affects the relationship between plasma concentration and target-site concentration, while elimination shapes the later decline in available compound. The cardiovascular response is consequently modeled as a transformed exposure trajectory: systemic concentration changes, target-compartment concentration changes, PDE5 interaction changes, NO–cGMP signaling changes, and smooth-muscle tone changes within the pathway model.
Concentration–effect transitions are central to interpreting vascular pathway behavior. During an ascending exposure phase, increasing target-site concentration can move the system through progressively greater modeled PDE5 interaction. Near a peak region, the concentration–effect relationship can approach a higher-engagement portion of the modeled curve. During decline, decreasing concentration can shift the system toward lower pathway engagement. Duration length can therefore be interpreted mechanistically as persistence of the concentration-dependent pathway state rather than as a clinical duration claim. Effectiveness is likewise used only as a mechanistic PD construct describing the degree of modeled pathway engagement relative to concentration and target interaction. The cardiovascular safety construct does not convert this pathway behavior into clinical outcomes. Instead, sildenafil and vardenafil are compared through the timing and geometry of PDE5 interaction, NO–cGMP signaling, and smooth-muscle relaxation as downstream components of their respective exposure trajectories.
The vascular signaling sequence also depends on the distinction between systemic exposure and local target exposure. Distribution can generate gradients between plasma and vascular compartments, while elimination progressively reduces systemic availability. Consequently, a change in plasma concentration does not necessarily produce an instantaneous or proportionally identical change in target-site signaling. This compartmental structure can introduce temporal offsets between exposure and vasodilatory pathway engagement. Sildenafil and vardenafil can therefore be modeled as different PK trajectories entering a related PD pathway involving PDE5, cGMP, NO-linked signaling, and smooth-muscle relaxation. Duration length describes the persistence of the modeled concentration–effect state, while the underlying vascular pathway remains dependent on target-site concentration. The mechanistic framework preserves the distinction between PK disposition and PD signaling: elimination changes exposure, distribution changes compartmental availability, and PDE5 interaction translates concentration into downstream pathway behavior.
Half-life and clearance describe important components of cardiovascular-relevant exposure persistence but do not independently define vascular pathway duration. Half life provides a characteristic measure of concentration decline under specified kinetic conditions, while elimination encompasses processes that remove drug from the systemic compartment. Metabolism contributes to clearance by transforming parent compound, including CYP-mediated pathways relevant to PDE5 inhibitor disposition. PK differences between sildenafil and vardenafil can therefore be represented through differences in clearance, distribution volume, metabolic turnover, and resulting concentration decay. These parameters shape the descending exposure trajectory that supplies the PD system with changing concentrations. Cardiovascular interpretation requires maintaining the distinction between exposure persistence and pathway persistence. A concentration may decline according to one kinetic phase while target-compartment concentration or downstream signaling follows another temporal pattern. Half-life is consequently one descriptor within a larger PK→PD framework, not a standalone measure of cardiovascular pathway behavior.
Clearance affects cardiovascular exposure geometry by controlling the rate at which systemic concentrations are removed after absorption and distribution. Metabolism can reduce parent-compound availability through biotransformation, while other elimination pathways contribute to total clearance. Elimination therefore determines the composite decline of systemic exposure, although redistribution can create additional phases. When concentration falls, the amount of compound available for vascular PDE5 interaction also changes according to target-compartment kinetics. The resulting PD trajectory can move through different concentration–effect regions as exposure declines. Half life helps describe this decay but does not capture every compartmental process. Sildenafil and vardenafil can consequently be compared through their disposition architecture rather than through a single persistence value. The cardiovascular PK construct remains descriptive: clearance changes concentration geometry, concentration geometry changes target availability, and target availability provides the temporal input for PDE5 interaction and downstream NO–cGMP signaling.
Terminal exposure behavior can further separate systemic concentration decline from local vascular pathway timing. A terminal phase may reflect redistribution, slow compartmental equilibration, or continuing elimination, depending on the kinetic model. This means that late plasma exposure cannot automatically be equated with persistence of vascular signaling. The relevant sequence remains absorption, distribution, metabolic transformation, elimination, target-compartment concentration, PDE5 interaction, and downstream signaling. PK differences can alter any of the disposition components, while metabolism and elimination contribute to the decline of parent-compound exposure. Half life provides a compact descriptor of concentration decay, but cardiovascular pathway persistence depends on the full exposure–response relationship. The mechanistic comparison therefore treats clearance and half-life as exposure determinants that shape the timing of concentration-dependent vascular pathway engagement rather than as direct measures of clinical cardiovascular safety.
| Clearance Component | PK Basis | Interpretation |
|---|---|---|
| Metabolic clearance | Biotransformation of parent compound | Reduces parent-compound exposure and contributes to the cardiovascular-relevant concentration decline. |
| CYP3A4-related clearance | CYP3A4-mediated oxidative metabolism | Provides a mechanistic pathway through which metabolic activity can modify exposure persistence. |
| Excretory clearance | Removal through excretory processes | Contributes to systemic drug removal and the later descending exposure trajectory. |
| Total clearance | Combined efficiency of relevant elimination pathways | Determines the overall rate of systemic exposure removal relative to distribution volume. |
| Half-life | Characteristic concentration-decay interval | Describes a component of exposure persistence but does not independently define vascular PD duration. |
| Terminal disposition | Late redistribution and elimination behavior | Shapes the tail of exposure geometry and the temporal context of late pathway engagement. |
Cardiovascular PK/PD variability describes dispersion in the mechanisms connecting exposure with vascular pathway engagement. Variability can occur in absorption, distribution, metabolism, elimination, target-compartment exposure, and concentration–effect coupling. Interindividual variability describes differences between modeled individuals in these parameters and trajectories. Clinical variability can be used descriptively as a category of observed dispersion, but it is not interpreted here as evidence of clinical outcomes. The cardiovascular safety framework therefore represents variability as a family of exposure and pathway trajectories rather than as a ranking. Differences in absorption can shift the ascending concentration phase, while distribution can change plasma-to-target timing. Metabolic and elimination differences can alter exposure persistence and decline. At the PD level, concentration-dependent PDE5 interaction and NO–cGMP signaling translate these PK differences into different modeled vascular pathway trajectories. The resulting dispersion is mechanistic and descriptive, with no implication of clinical benefit, harm, or effectiveness.
Timing geometry can be affected by variability at several sequential levels. A difference in systemic input can alter when a target-relevant concentration is reached. A distribution difference can introduce a delay or gradient between plasma concentration and vascular-compartment concentration. Metabolism and elimination can modify the later decline, while the concentration–effect relationship determines how those changing concentrations are translated into PDE5 interaction and downstream NO–cGMP signaling. The resulting cardiovascular pathway trajectory may therefore differ in its ascending phase, peak region, persistence, or decline. Variability is consequently propagated through the PK→PD chain rather than confined to a single parameter. Interindividual variability describes differences among such trajectories, whereas clinical variability remains a descriptive label without outcome interpretation. Sildenafil and vardenafil can be compared through this trajectory structure while preserving the distinction between exposure geometry and vascular pathway engagement.
The final mechanistic representation is a coupled set of concentration–time and pathway-engagement curves. Early exposure geometry establishes the temporal position of PDE5 interaction, while later exposure persistence determines how the modeled NO–cGMP signaling environment changes during concentration decline. Distribution can produce compartmental offsets, and metabolic or elimination processes can reshape the descending trajectory. Variability in any of these components produces corresponding variability in modeled vasodilation timing and hemodynamic coupling. The important distinction is that a cardiovascular PK difference is not itself a cardiovascular PD difference: PK determines concentration availability, whereas PD describes the translation of concentration into molecular and vascular pathway engagement. Cardiovascular safety is therefore treated solely as a mechanistic PK/PD construct. The framework does not infer real-world effectiveness or clinical outcomes. Instead, it describes how exposure geometry, PDE5 interaction, NO–cGMP signaling, smooth-muscle relaxation, and systemic hemodynamic transitions can be coupled into a neutral mechanistic model.
The principal cardiovascular PK determinants are absorption, distribution, metabolism, and elimination because these processes establish the concentration trajectory available for vascular target interaction. Absorption controls the rate and extent of systemic entry and therefore influences the early ascending phase. Distribution determines movement between plasma and other compartments and can create gradients between systemic concentration and concentration near vascular targets. Metabolism transforms the parent compound and contributes to its decline, while elimination integrates processes responsible for removing drug from the systemic compartment. These mechanisms collectively form exposure geometry, including the rise, peak region, decline, and terminal phases. Cardiovascular PK interpretation then uses that geometry as the temporal input to pharmacodynamic pathway engagement. The mechanisms describe exposure formation and persistence; they do not independently constitute clinical cardiovascular outcomes or establish clinical safety conclusions.
The principal cardiovascular PD determinants include PDE5 interaction, NO–cGMP signaling, target-compartment concentration, and smooth-muscle relaxation. Once a PDE5 inhibitor reaches the relevant compartment, its concentration determines the degree of modeled interaction with PDE5. PDE5 inhibition changes cGMP degradation within the relevant signaling environment, which can modify the persistence of cGMP-mediated signaling. This provides a molecular connection to vascular smooth-muscle relaxation and vasodilatory pathway behavior. The PD trajectory therefore depends on concentration and time rather than on a single fixed parameter. Distribution can influence the concentration reaching the target compartment, while elimination shapes the later decline in available compound. Cardiovascular PD interpretation consequently represents a transformation of the exposure trajectory into molecular and vascular pathway behavior. These mechanisms are described without translating them into clinical effectiveness, clinical benefit, or clinical outcome claims.
Vasodilation geometry describes the temporal pattern by which concentration-dependent vascular pathway engagement develops and changes. It begins with systemic exposure, followed by distribution into relevant compartments, PDE5 interaction, modulation of cGMP degradation, and downstream NO–cGMP signaling. Smooth-muscle relaxation is then represented as a downstream component of this pathway. The geometry can contain an ascending phase as concentration increases, a higher-engagement region near peak exposure, and a declining phase as concentration falls. The timing of each phase depends on both PK exposure and PD coupling. Distribution can create delays between plasma concentration and target-compartment concentration, while metabolism and elimination shape later exposure decline. Vasodilation geometry is therefore not equivalent to a single measured concentration or time point. It is a mechanistic representation of how changing exposure is translated into changing vascular pathway engagement.
Exposure geometry determines when and how much drug is available for cardiovascular target interaction across time. The ascending portion is influenced by systemic input from absorption, while distribution shapes movement between plasma and target-related compartments. The peak region reflects the balance between ongoing input and disposition, and the declining portion reflects distribution, metabolism, and elimination. These changing concentrations provide the temporal input for PDE5 interaction and NO–cGMP signaling. Consequently, a change in exposure geometry can shift the timing of modeled concentration–effect transitions without changing the molecular identity of the target. Plasma concentration and target-compartment concentration may also differ because of distribution gradients. The cardiovascular PK/PD relationship is therefore a coupled trajectory rather than a direct one-to-one mapping between a single concentration and a vascular response. Exposure geometry supplies the timing and magnitude of the input, while PD mechanisms determine its downstream pathway translation.
Concentration–effect transitions describe changes in modeled vascular pathway engagement as target-relevant drug concentration changes. During an ascending exposure phase, increasing concentration can produce progressively greater modeled PDE5 interaction. This can alter cGMP degradation and the downstream NO–cGMP signaling environment. Near a higher concentration region, the concentration–effect relationship may approach a different portion of its modeled curve. During decline, decreasing concentration can shift pathway engagement in the opposite direction. These transitions depend on target-compartment concentration rather than necessarily on plasma concentration alone. Distribution can therefore introduce temporal offsets, while metabolism and elimination influence how long changing concentrations persist. The resulting cardiovascular trajectory is a mechanistic sequence linking exposure to PDE5 interaction, cGMP signaling, smooth-muscle relaxation, and vasodilatory pathway behavior. Concentration–effect transitions are not treated as clinical endpoints; they describe the modeled movement between different states of molecular pathway engagement.
Half-life describes a characteristic aspect of concentration decline under specified kinetic conditions, so it can help characterize the persistence of systemic exposure. It does not, by itself, define cardiovascular pathway duration or the complete timing of vascular signaling. Distribution can create multiple kinetic phases, and target-compartment concentration may not decline in parallel with plasma concentration. Metabolism and elimination also contribute to the overall exposure trajectory. Consequently, cardiovascular timing depends on the combined sequence of absorption, distribution, target-compartment equilibration, PDE5 interaction, downstream signaling, metabolism, and elimination. A half-life value provides information about one aspect of this sequence, particularly concentration decay, but does not replace the complete exposure–response model. Mechanistically, the relevant question is how the changing concentration reaches the vascular target and how that concentration is translated into PDE5 and NO–cGMP pathway engagement over time.
Distribution gradients occur when drug concentrations differ between plasma and other compartments, including compartments relevant to vascular target interaction. After systemic absorption, drug may require time to move from plasma into tissue or equilibrate between compartments. This creates a possible temporal difference between the plasma concentration trajectory and the concentration available near the target. During concentration decline, redistribution can also cause local concentrations to decrease at a different rate from plasma concentrations. These gradients matter because PDE5 interaction depends on concentration at the relevant molecular site rather than necessarily on the instantaneous plasma concentration. Cardiovascular pathway timing is therefore influenced by both systemic exposure and compartmental movement. A plasma concentration can rise before target-compartment concentration reaches a corresponding region, or plasma decline can occur while another compartment remains relatively persistent. Distribution consequently adds spatial and temporal structure to the PK→PD relationship.
Metabolism interacts with cardiovascular exposure by transforming the parent compound and altering its availability for continued target interaction. Metabolic turnover contributes to the descending portion of the concentration–time trajectory after systemic absorption and distribution. CYP3A4-mediated metabolism is an important mechanistic pathway in the disposition of both sildenafil and vardenafil. Changes in metabolic activity can therefore alter the rate at which parent-compound exposure declines and modify the temporal environment in which PDE5 interaction occurs. Metabolism is a PK process rather than a direct vascular signaling mechanism. Its cardiovascular relevance comes from changing the concentration input supplied to the PD system. The resulting concentration trajectory then determines the temporal availability of drug for PDE5 interaction, NO–cGMP signaling, and smooth-muscle pathway engagement. Metabolism can thus influence exposure persistence and timing without being interpreted as a direct measure of cardiovascular clinical safety or outcome.
Elimination interacts with cardiovascular pathway behavior by controlling the progressive removal of drug from the systemic compartment. As elimination reduces systemic concentration, less parent compound becomes available for distribution and target interaction, although compartmental redistribution can create additional temporal phases. The resulting decline influences the concentration available for PDE5 interaction and therefore the downstream NO–cGMP signaling trajectory. Elimination includes metabolic and excretory processes and should be distinguished from the downstream PD mechanisms themselves. A change in elimination can modify exposure persistence, but the vascular pathway still depends on target-compartment concentration and concentration–effect coupling. Distribution can also create a delay between systemic elimination and local concentration decline. Consequently, cardiovascular timing emerges from the combined geometry of exposure and pathway engagement rather than from elimination alone. The mechanistic interpretation remains descriptive and does not convert altered exposure persistence into a clinical safety conclusion.
Mechanistic cardiovascular variability describes differences in the PK and PD parameters that shape exposure-driven vascular pathway trajectories. PK variability can involve absorption rate, distribution, metabolic turnover, clearance, and elimination. PD variability can involve the relationship between target concentration and PDE5 interaction or the translation of PDE5 modulation into NO–cGMP signaling and smooth-muscle relaxation. Interindividual differences can therefore produce different concentration–time and concentration–effect trajectories. Some trajectories may rise more rapidly, show different compartmental gradients, or decline at different rates. Such variability can alter the modeled timing of pathway engagement without establishing a particular clinical outcome. The framework separates exposure variability from PD coupling variability so that changes in systemic concentration are not automatically interpreted as changes in vascular signaling. Mechanistic cardiovascular variability is consequently the dispersion of coupled PK/PD trajectories, not a ranking of clinical safety or effectiveness.